NEW YORK (GenomeWeb News) – Coverage of Foundation Medicine was initiated today by Goldman Sachs and Leerink Swann, which gave the cancer genomics analysis firm a Neutral and Outperform rating, respectively.

Goldman Sachs gave the company a six-month share target price of $33, while Leerink Swann gave it a $39 price target. The two investment banks were underwriters in Foundation's initial pubic offering.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.